A randomized, double-blind, placebo-controlled phase II study to investigate the efficacy and safety of riociguat (0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID) in patients with symptomatic pulmonary hypertension associated with idiopathic interstitial pneumonias (IIP).
2022-06-29
عنوان الدراسة
A randomized, double-blind, placebo-controlled phase II study to investigate the efficacy and safety of riociguat (0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID) in patients with symptomatic pulmonary hypertension associated with idiopathic interstitial pneumonias (IIP).
داعم الدراسة
Bayer
دواء الدراسة
Riociguat
رقم بروتوكول الدراسة
BAY 63-2521 / 13605
حالة الدراسة
Completed
موقع الدراسة
KFMC
مرحلة الدراسة
2
Comments and Suggestions
For any inquiries or comments about the government services, please fill in the required information.